Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001
Timber PharmaceuticalsApril 28, 2021 GMT
- Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis -
Basking Ridge, NJ, April 28, 2021 (GLOBE NEWSWIRE) via NewMediaWire Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Japanese Patent Office has decided to grant a patent (No. 2018-542677) for its lead asset, TMB-001, the Company’s topical pharmaceutical composition of isotretinoin that is currently being evaluated for the treatment of moderate to severe subtypes of congenital ichthyosis (CI).
Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001
Timber PharmaceuticalsDecember 15, 2020 GMT
- Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition -
WOODCLIFF LAKE, NJ - ( NewMediaWire ) - December 15, 2020 - Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO) for the Company’s patent application covering its pharmaceutical isotretinoin composition (U.S. Patent Application No.: 15/772,456).
News Category Global Banking & Finance Reviews
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
BOSTON, Dec. 11, 2020 Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors.
“I am thrilled to welcome both Camille and Lynn to our Board of Directors, as both leaders have tremendous experience building and leading teams that work effectively to bring new medicines to patients in need,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.